ACRS Aclaris Therapeutics Inc

Price (delayed)

$21.65

Market cap

$1.13B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.4

Enterprise value

$1.1B

Sector: Healthcare
Industry: Biotechnology

Highlights

ACRS's equity has soared by 198% QoQ and by 93% YoY
Aclaris Therapeutics's quick ratio has surged by 141% QoQ and by 129% YoY
Aclaris Therapeutics's EPS has surged by 58% YoY but it has decreased by 17% QoQ
The company's net income has surged by 54% YoY but it fell by 26% QoQ

Key stats

What are the main financial stats of ACRS
Market
Shares outstanding
52.11M
Market cap
$1.13B
Enterprise value
$1.1B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
9.99
Price to sales (P/S)
159.05
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
161.15
Earnings
Revenue
$6.85M
EBIT
-$64.37M
EBITDA
-$63.33M
Free cash flow
-$44.39M
Per share
EPS
-$1.4
Free cash flow per share
-$0.88
Book value per share
$2.17
Revenue per share
$0.14
TBVPS
$3.07
Balance sheet
Total assets
$161.4M
Total liabilities
$49.11M
Debt
$11.32M
Equity
$112.29M
Working capital
$120M
Liquidity
Debt to equity
0.1
Current ratio
9.27
Quick ratio
8.9
Net debt/EBITDA
0.38
Margins
EBITDA margin
-924.2%
Gross margin
26.1%
Net margin
-936.7%
Operating margin
-693.2%
Efficiency
Return on assets
-66%
Return on equity
-106.9%
Return on invested capital
-111.8%
Return on capital employed
-43.8%
Return on sales
-939.4%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

ACRS stock price

How has the Aclaris Therapeutics stock price performed over time
Intraday
2.17%
1 week
-7.12%
1 month
-18.85%
1 year
1,578.29%
YTD
234.62%
QTD
-14.09%

Financial performance

How have Aclaris Therapeutics's revenue and profit performed over time
Revenue
$6.85M
Gross profit
$1.79M
Operating income
-$47.5M
Net income
-$64.18M
Gross margin
26.1%
Net margin
-936.7%
ACRS's net margin has soared by 71% YoY but it is down by 19% from the previous quarter
Aclaris Therapeutics's operating margin has soared by 69% YoY and by 12% from the previous quarter
The company's revenue has surged by 57% YoY and by 6% QoQ
The company's net income has surged by 54% YoY but it fell by 26% QoQ

Growth

What is Aclaris Therapeutics's growth rate over time

Valuation

What is Aclaris Therapeutics stock price valuation
P/E
N/A
P/B
9.99
P/S
159.05
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
161.15
Aclaris Therapeutics's EPS has surged by 58% YoY but it has decreased by 17% QoQ
ACRS's equity has soared by 198% QoQ and by 93% YoY
ACRS's P/B is 194% above its 5-year quarterly average of 3.4 and 72% above its last 4 quarters average of 5.8
ACRS's P/S is 146% above its last 4 quarters average of 64.6
The company's revenue has surged by 57% YoY and by 6% QoQ

Efficiency

How efficient is Aclaris Therapeutics business performance
Aclaris Therapeutics's return on sales has surged by 71% YoY but it has decreased by 19% QoQ
Aclaris Therapeutics's return on invested capital has increased by 44% YoY and by 23% QoQ
The company's return on equity rose by 33% YoY and by 2.6% QoQ
The ROA has increased by 32% YoY but it has decreased by 4.9% from the previous quarter

Dividends

What is ACRS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ACRS.

Financial health

How did Aclaris Therapeutics financials performed over time
Aclaris Therapeutics's quick ratio has surged by 141% QoQ and by 129% YoY
ACRS's current ratio has surged by 140% since the previous quarter and by 131% year-on-year
ACRS's debt is 90% less than its equity
ACRS's equity has soared by 198% QoQ and by 93% YoY
The debt to equity has dropped by 67% since the previous quarter and by 47% year-on-year

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.